Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.

نویسندگان

  • C E van Iperen
  • C A Gaillard
  • R J Kraaijenhagen
  • B G Braam
  • J J Marx
  • A van de Wiel
چکیده

OBJECTIVES Critically ill patients often are anemic, which may impair oxygen delivery. Transfusion of red cells and supplementation with vitamins or iron are the usual therapeutic strategies, whereas only sporadic data are available on the use of epoetin alfa in these patients. We investigated endogenous erythropoietin (EPO) production and the response to epoetin alfa in anemic intensive care unit (ICU) patients. DESIGN Randomized, open trial. SETTING Multidisciplinary ICU in a single secondary care center. PATIENTS Thirty-six critically ill patients admitted to the ICU who became anemic (hemoglobin concentration, <11.2 g/dL or <12.1 g/dL in case of cardiac disease) were randomized to one of three study groups. INTERVENTIONS All patients received folic acid (1 mg) daily. The control group received no additional therapy, the iron group received 20 mg of iron saccharate intravenously (iv) daily for 14 days. The EPO group received iv iron and epoetin alfa (300 IU/kg) subcutaneously on days 1, 3, 5, 7, and 9. MEASUREMENTS AND MAIN RESULTS Blood and reticulocyte counts were measured daily for 22 days. Serum EPO, C-reactive protein, serum transferrin receptor, and iron variables were measured on days 0, 2, 6, 10, and 21. Blood loss and red cell transfusions were recorded. Serum EPO concentrations were inappropriately low for the degree of anemia at baseline, with no difference between patients with and without renal failure. Exogenous administration of EPO increased EPO concentrations from 23+/-13 to a maximum of 166+/-98 units/L on day 10 (p < .05). Reticulocyte count increased exclusively in the EPO group from 56+/-33 x 10(9)/L to a maximum of 189+/-97 on day 13 (p < .05). Serum transferrin receptor rose only in the EPO group from 3.7+/-1.4 to 8.6+/-3.1 mg/L on day 10 (p < .05) and remained elevated on day 21, indicating an increase in erythropoiesis. Hemoglobin concentration and platelet count remained identical in the three study groups. CONCLUSION Endogenous EPO concentrations are low in critically ill patients. The bone marrow of these patients is able to respond to exogenous epoetin alfa, as shown by elevated concentrations of reticulocytes and serum transferrin receptors.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pathophysiology of intensive care unit-acquired anemia

The formation of red blood cells (RBCs) in the bone marrow is regulated by erythropoietin in response to a cascade of events. Anemia in the intensive care unit can be caused by a host of factors. Patients in the intensive care unit may have decreased RBC production and a blunted response to erythropoietin. Administration of recombinant human erythropoietin may stimulate erythropoiesis, increase...

متن کامل

Anaemia of critical illness-- implications for understanding and treating rHuEPO resistance.

The prospect of a shortage of blood for transfusions, increasing awareness of the adverse effects of transfusions, and the availability of human recombinant erythropoietin (rHuEPO) have stimulated interest in the pathogenesis of the anaemia of intensive care unit (ICU) patients. As in the anaemia of chronic illness or chronic renal failure (CRF), the anaemia of ICU patients is a multifactorial ...

متن کامل

Impact of erythropoietin on intensive care unit patients.

Anemia is common in intensive care unit (ICU) patients. Red blood cell (RBC) transfusions are mainstays of their treatment and can be life-saving. Allogeneic blood components inherently bear risks of infection and immune reactions. Although these risks are rare in developed countries, recombinant human erythropoietin (rhEpo) and other erythropoiesis-stimulating agents (ESAs) have been considere...

متن کامل

Effects of Recombinant Human Erythropoietin (rHuEpo) on the Blood Cells and Hematopoiesis in Spleen of Rats

Recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. In clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (Epo) increase CFU-E and diminish the number of granulocytes formed per culture plate. Fetal progenitors are more sensitive to these effects of Epo than progenitors from adults. We administered doses 50, 100, 200 IU/...

متن کامل

PHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS

The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Critical care medicine

دوره 28 8  شماره 

صفحات  -

تاریخ انتشار 2000